G Protein News and Research

RSS

Scientists reassess heart disease causes

Almost 3,000 Northern Ireland people are to take part in a Queen's study analysing their risks of developing heart disease in the future.

17 Oct 2007

New technique to probe the dynamics of the Holliday junction

The Holliday junction is a four-stranded DNA structure that forms during a process known as homologous recombination, which occurs when damaged DNA is repaired. Understanding how DNA repairs itself is an essential step in ultimately developing therapies for genetic disorders.

17 Oct 2007

New knowledge about basic cancer biology

Merging technological innovations and new knowledge about basic cancer biology, cancer researchers now target specific molecules involved in critical chemical pathways of cancerous cells.

17 Oct 2007

Liver fibrosis will be treated by a potential target

The outcome of hepatitis is either self recovery or its development into liver fibrosis or, further, liver cirrhosis.

17 Oct 2007

Insulin signaling and amphetamines

Abuse of psychostimulants such as amphetamine remains a serious public health concern.

17 Oct 2007

Comparative genome analysis of fungi brings new knowledge to develop protein production

VTT's Research Scientist Mikko Arvas presents his doctoral thesis on 19 October at 12 at the University of Helsinki, Finland.

17 Oct 2007

Scientists map flu's chemical key

Scientists from Baylor College of Medicine (BCM) and Rice University have developed a three-dimensional, molecular map that could yield clues about the genetic mutations that will allow bird flu to spread among humans.

17 Oct 2007

Strain of the bacteria Streptococcus pneumoniae that causes ear infections emerges; resistant to antibiotics, pneumococcal vaccine

A strain of the bacteria Streptococcus pneumoniae, which can cause ear infections in children, has been detected that is resistant to all FDA-approved antibiotics for treatment of ear infections and is not covered by the pneumococcal 7-valent conjugate vaccine, according to a study in the October 17 issue of JAMA.

17 Oct 2007

Contraceptive pill with no side-effects in the pipeline

Scientists in the United States are developing a new contraceptive pill with no side-effects.

17 Oct 2007

Optical coherence tomography helps track multiple sclerosis

A five-minute eye exam might prove to be an inexpensive and effective way to gauge and track the debilitating neurological disease multiple sclerosis, potentially complementing costly magnetic resonance imaging to detect brain shrinkage - a characteristic of the disease's progression.

16 Oct 2007

Researchers specifically manipulate tumor angiogenesis gene

Angiogenesis is a common process that is essential for tumor growth beyond 2 mm. Although numerous growth factors are involved, vascular endothelial growth factor (VEGF), particularly VEGF-A, has been shown to play an important role in tumor angiogenesis.

16 Oct 2007

Newly solved structure reveals how cells resist oxygen damage

The sun's rays give life, but also take it away. Singlet oxygen, a byproduct of the photosynthetic process by which certain cells convert sunlight into energy, is a highly toxic and reactive substance that tears cells apart.

16 Oct 2007

Researchers working on the development of drugs to limit neuronal death

Neurons die en masse when the spinal cord is injured or when a person suffers a stroke. Researchers of the Max Delbrueck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, and of Aarhus University, Denmark, have unraveled the molecular mechanism which causes the death not only of damaged neurons, but also of healthy nerve cells.

16 Oct 2007

Homocysteine appears to be play a part in retinal damage and vision loss

Homocysteine, an amino acid believed to contribute to heart attack, stroke and dementia, likely also is a player in retinal damage and vision loss, researchers say.

16 Oct 2007

New insight into Herceptin resistance in breast cancer

A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab (Herceptin). The research, published by Cell Press in the October issue of the journal Cancer Cell , identifies markers that may help to identify patients who are unlikely to respond to trastuzumab treatment and provides a potential strategy for treating these patients.

16 Oct 2007